S&P 500   3,950.63 (+0.87%)
DOW   32,235.84 (+1.17%)
QQQ   305.12 (-0.08%)
AAPL   157.47 (+1.59%)
MSFT   270.61 (-3.16%)
META   197.74 (+1.09%)
GOOGL   101.17 (-0.44%)
AMZN   97.32 (-1.65%)
TSLA   183.33 (+1.78%)
NVDA   258.28 (+0.40%)
NIO   8.69 (+5.21%)
BABA   80.89 (-0.96%)
AMD   96.03 (-1.85%)
T   18.49 (+1.99%)
F   11.23 (-0.62%)
MU   57.36 (+1.24%)
CGC   1.87 (-6.50%)
GE   89.81 (-0.53%)
DIS   94.02 (+0.88%)
AMC   4.33 (+3.59%)
PFE   40.75 (+1.62%)
PYPL   73.02 (+0.04%)
NFLX   304.65 (+0.38%)
S&P 500   3,950.63 (+0.87%)
DOW   32,235.84 (+1.17%)
QQQ   305.12 (-0.08%)
AAPL   157.47 (+1.59%)
MSFT   270.61 (-3.16%)
META   197.74 (+1.09%)
GOOGL   101.17 (-0.44%)
AMZN   97.32 (-1.65%)
TSLA   183.33 (+1.78%)
NVDA   258.28 (+0.40%)
NIO   8.69 (+5.21%)
BABA   80.89 (-0.96%)
AMD   96.03 (-1.85%)
T   18.49 (+1.99%)
F   11.23 (-0.62%)
MU   57.36 (+1.24%)
CGC   1.87 (-6.50%)
GE   89.81 (-0.53%)
DIS   94.02 (+0.88%)
AMC   4.33 (+3.59%)
PFE   40.75 (+1.62%)
PYPL   73.02 (+0.04%)
NFLX   304.65 (+0.38%)
S&P 500   3,950.63 (+0.87%)
DOW   32,235.84 (+1.17%)
QQQ   305.12 (-0.08%)
AAPL   157.47 (+1.59%)
MSFT   270.61 (-3.16%)
META   197.74 (+1.09%)
GOOGL   101.17 (-0.44%)
AMZN   97.32 (-1.65%)
TSLA   183.33 (+1.78%)
NVDA   258.28 (+0.40%)
NIO   8.69 (+5.21%)
BABA   80.89 (-0.96%)
AMD   96.03 (-1.85%)
T   18.49 (+1.99%)
F   11.23 (-0.62%)
MU   57.36 (+1.24%)
CGC   1.87 (-6.50%)
GE   89.81 (-0.53%)
DIS   94.02 (+0.88%)
AMC   4.33 (+3.59%)
PFE   40.75 (+1.62%)
PYPL   73.02 (+0.04%)
NFLX   304.65 (+0.38%)
S&P 500   3,950.63 (+0.87%)
DOW   32,235.84 (+1.17%)
QQQ   305.12 (-0.08%)
AAPL   157.47 (+1.59%)
MSFT   270.61 (-3.16%)
META   197.74 (+1.09%)
GOOGL   101.17 (-0.44%)
AMZN   97.32 (-1.65%)
TSLA   183.33 (+1.78%)
NVDA   258.28 (+0.40%)
NIO   8.69 (+5.21%)
BABA   80.89 (-0.96%)
AMD   96.03 (-1.85%)
T   18.49 (+1.99%)
F   11.23 (-0.62%)
MU   57.36 (+1.24%)
CGC   1.87 (-6.50%)
GE   89.81 (-0.53%)
DIS   94.02 (+0.88%)
AMC   4.33 (+3.59%)
PFE   40.75 (+1.62%)
PYPL   73.02 (+0.04%)
NFLX   304.65 (+0.38%)

Celldex Therapeutics - CLDX Stock Forecast, Price & News

$41.70
-0.14 (-0.33%)
(As of 03/20/2023 03:39 PM ET)
Add
Compare
Today's Range
$39.57
$41.80
50-Day Range
$40.12
$47.43
52-Week Range
$19.85
$48.40
Volume
516,715 shs
Average Volume
433,531 shs
Market Capitalization
$1.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.67

Celldex Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
62.0% Upside
$66.67 Price Target
Short Interest
Bearish
7.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.58) to ($2.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

851st out of 983 stocks

Diagnostic Substances Industry

11th out of 14 stocks


CLDX stock logo

About Celldex Therapeutics (NASDAQ:CLDX) Stock

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CLDX Stock News Headlines

Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
CLDX.A
As Celldex Recovers, Here's My Strategy
CLDX.A - | Stock Price & Latest News | Reuters
SVB Securities Keeps Their Buy Rating on Celldex (CLDX)
Celldex Therapeutics (NASDAQ: CLDX)
See More Headlines
Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CLDX Company Calendar

Last Earnings
11/09/2021
Today
3/20/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CLDX
CUSIP
15117B10
Employees
132
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$66.67
High Stock Price Forecast
$73.00
Low Stock Price Forecast
$63.00
Forecasted Upside/Downside
+63.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-112,320,000.00
Net Margins
-4,765.59%
Pretax Margin
-4,765.59%

Debt

Sales & Book Value

Annual Sales
$2.36 million
Book Value
$6.93 per share

Miscellaneous

Free Float
45,932,000
Market Cap
$1.93 billion
Optionable
Optionable
Beta
2.17

Social Links


Key Executives

  • Anthony S. Marucci
    President, Chief Executive Officer & Director
  • Sam Martin
    CFO, Secretary, Treasurer & Senior Vice President
  • Tibor Keler
    Chief Scientific Officer & Executive VP
  • Diane C. YoungDiane C. Young
    Chief Medical Officer & Senior Vice President
  • Elizabeth CrowleyElizabeth Crowley
    Chief Product Development Officer & Senior VP













CLDX Stock - Frequently Asked Questions

Should I buy or sell Celldex Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLDX shares.
View CLDX analyst ratings
or view top-rated stocks.

What is Celldex Therapeutics' stock price forecast for 2023?

3 brokerages have issued 1-year target prices for Celldex Therapeutics' stock. Their CLDX share price forecasts range from $63.00 to $73.00. On average, they anticipate the company's share price to reach $66.67 in the next year. This suggests a possible upside of 59.3% from the stock's current price.
View analysts price targets for CLDX
or view top-rated stocks among Wall Street analysts.

How have CLDX shares performed in 2023?

Celldex Therapeutics' stock was trading at $44.57 at the beginning of 2023. Since then, CLDX stock has decreased by 6.1% and is now trading at $41.84.
View the best growth stocks for 2023 here
.

When is Celldex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our CLDX earnings forecast
.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.09. The biopharmaceutical company earned $0.15 million during the quarter, compared to the consensus estimate of $1.70 million. Celldex Therapeutics had a negative net margin of 4,765.59% and a negative trailing twelve-month return on equity of 28.90%.

When did Celldex Therapeutics' stock split?

Shares of Celldex Therapeutics reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Jennison Associates LLC (3.30%), Geode Capital Management LLC (1.88%), Price T Rowe Associates Inc. MD (1.77%), Marshall Wace LLP (1.42%), Eversept Partners LP (1.19%) and Fred Alger Management LLC (1.11%). Insiders that own company stock include Anthony S Marucci, Diane C Young, Elizabeth Crowley, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, Sarah Cavanaugh and Tibor Keler.
View institutional ownership trends
.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $41.84.

How much money does Celldex Therapeutics make?

Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.98 billion and generates $2.36 million in revenue each year. The biopharmaceutical company earns $-112,320,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis.

How many employees does Celldex Therapeutics have?

The company employs 132 workers across the globe.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for the company is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 454-7120, via email at ir@celldextherapeutics.com, or via fax at 908-454-1911.

This page (NASDAQ:CLDX) was last updated on 3/20/2023 by MarketBeat.com Staff